# (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

> **NCT01100112** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT01100112
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100112, "(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01100112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*